(2022) Levels and Trends of Maternal Mortality and Morbidity by Cause in North Africa and Middle East, 1990 to 2019: An Analysis for the Global Burden of Disease Study 2019. Archives of Iranian Medicine. pp. 666-675. ISSN 1029-2977

(2022) Maternal Mortality and Morbidity by Cause in Provinces of Iran, 1990 to 2019: An Analysis for the Global Burden of Disease Study 2019. Archives of Iranian Medicine. pp. 578-590. ISSN 1029-2977

(2022) Neonate, Infant, and Child Mortality by Cause in Provinces of Iran: An Analysis for the Global Burden of Disease Study 2019. Archives of Iranian Medicine. pp. 484-495. ISSN 1029-2977

(2021) Cancer in Iran 2008 to 2025: Recent incidence trends and short-term predictions of the future burden. International Journal of Cancer. pp. 594-605. ISSN 0020-7136

(2021) Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. p. 172. ISSN 1537-6591 (Electronic) 1058-4838 (Linking)

(2021) Erratum: SD1000: High Sustained Viral Response Rate in 1361 Patients with Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial (Clin Infect Dis (2020) 70:10 (2206-2212) DOI: 10.1093/cid/ciz628). Clinical Infectious Diseases. p. 172. ISSN 10584838 (ISSN)

(2021) Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease study 2019. BMJ Global Health. ISSN 20597908 (ISSN)

(2021) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial (vol 70, pg 2206, 2020). Clinical Infectious Diseases. p. 172. ISSN 1058-4838

(2020) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases. pp. 2206-2212. ISSN 1058-4838

(2019) Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry. Cancer Epidemiology. pp. 50-58. ISSN 1877-7821

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504